| Leader, Project |
NCT06696716: ONO-4059 Study in Patients With Steroid-resistant Pemphigus |
|
|
| Recruiting | 3 | 34 | Japan | ONO-4059, Tirabrutinib hydrochloride, ONO-4059 placebo | Ono Pharmaceutical Co. Ltd | Pemphigus, Steroid-resistant Pemphigus | 09/27 | 03/29 | | |
| Completed | 3 | 800 | Japan, RoW | Nivolumab, BMS-936558, ONO-4538, MDX-1106, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Capecitabine, Placebo | Ono Pharmaceutical Co. Ltd, Bristol-Myers Squibb | Gastric Cancer | 08/22 | 03/23 | | |
|
NCT05144854: A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) |
|
|
| Active, not recruiting | 3 | 626 | Japan, RoW | ONO-4538, Nivolumab, Opdivo, Ipilimumab, BMS-734016, Yervoy, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium | Ono Pharmaceutical Co. Ltd | Gastric Cancer | 05/26 | 05/27 | | |
NCT06538272: Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel |
|
|
| Active, not recruiting | 2 | 210 | Japan | ONO-2910, Placebo | Ono Pharmaceutical Co. Ltd | CIPN - Chemotherapy-Induced Peripheral Neuropathy | 02/25 | 06/25 | | |
NCT06256328: A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) |
|
|
| Active, not recruiting | 2 | 210 | Japan, RoW | ONO-4578, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium, Nivolumab, Opdivo, Placebo | Ono Pharmaceutical Co. Ltd | Gastric Cancer | 11/25 | 07/27 | | |
NCT06622941: Study to ONO-4538 in Patients With Rhabdoid Tumor |
|
|
| Recruiting | 2 | 23 | Japan | ONO-4538, Nivolumab | Ono Pharmaceutical Co. Ltd | Rhabdoid Tumor | 01/29 | 03/30 | | |
NCT06752603: A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis |
|
|
| Not yet recruiting | 2 | 50 | NA | ONO-1110, Placebo | Ono Pharmaceutical Co. Ltd | Hunner Type Interstitial Cystitis | 06/26 | 08/26 | | |
NCT06752590: A Clinical Study of ONO-1110 in Patients With Fibromyalgia |
|
|
| Not yet recruiting | 2 | 160 | NA | ONO-1110, Placebo | Ono Pharmaceutical Co. Ltd | Fibromyalgia | 07/26 | 09/26 | | |
NCT06708416: A Study of ONO-1110 in Patients With Postherpetic Neuralgia |
|
|
| Not yet recruiting | 2 | 140 | NA | ONO-1110, Placebo | Ono Pharmaceutical Co. Ltd | Postherpetic Neuralgia (PHN) | 06/26 | 08/26 | | |
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy |
|
|
| Recruiting | 2 | 80 | US | ONO-2808, Placebo | Ono Pharmaceutical Co. Ltd | Multiple System Atrophy (MSA) | 08/25 | 08/25 | | |
| Recruiting | 2 | 59 | Japan, RoW | ONO-4538, oxaliplatin, S-1, capecitabine, bevacizumab, temozolomide | Ono Pharmaceutical Co. Ltd | Pan-tumor | 12/26 | 12/26 | | |
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study) |
|
|
| Recruiting | 2 | 112 | US | Tirabrutinib, ONO-4059 | Ono Pharmaceutical Co. Ltd | Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma | 03/27 | 03/27 | | |
NCT03176277: A Study of ONO-7475 in Patients With Acute Leukemias |
|
|
| Terminated | 1/2 | 42 | US | ONO-7475 3mg once daily, Part A initial dose level, ONO-7475 6mg once daily, Part A 2nd dose level, ONO-7475 10mg once daily, Part A 3rd dose level, ONO-7475 6mg + Venetoclax (70-400mg), ONO-7475 + Venetoclax Combination | Ono Pharmaceutical Co. Ltd | Acute Leukemia, Myelodysplastic Syndromes | 12/22 | 01/23 | | |
NCT06547385: Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer |
|
|
| Active, not recruiting | 1 | 40 | Japan | ONO-4578, ONO-4538, Nivolumab, Capecitabine, XELODA, Oxaliplatin, ELPLAT, Fluorouracil, 5-FU, Calcium Levofolinate Hydrateb, ISOVORIN, Bevacizumab, AVASTIN | Ono Pharmaceutical Co. Ltd | Colorectal Cancer | 10/27 | 10/27 | | |
ONO-4578-04, NCT06538207: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer |
|
|
| Active, not recruiting | 1 | 46 | Japan | ONO-4578, ONO-4538, Nivolumab, Oxaliplatin, Levofolinate, Irinotecan, Fluorouracil, Gemcitabine, Nab-Paclitaxel | Ono Pharmaceutical Co. Ltd | Metastatic Pancreatic Cancer | 10/24 | 03/25 | | |
NCT06542731: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 42 | Japan | ONO-4578, ONO-4538, Nivolumab, Docetaxel, Taxotere, Ramucirumab, Cyramza | Ono Pharmaceutical Co. Ltd | Non-small Cell Lung Cancer | 09/26 | 12/26 | | |
NCT06532344: An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer |
|
|
| Active, not recruiting | 1 | 32 | Japan | ONO-7913, Magrolimab, ONO-4538, Nivolumab, Oxaliplatin, Levofolinate, Irinotecan, Fluorouracil | Ono Pharmaceutical Co. Ltd | Metastatic Pancreatic Cancer | 12/26 | 12/26 | | |
NCT06525246: Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 78 | Japan | ONO-7475, Osimertinib Mesylate | Ono Pharmaceutical Co. Ltd | Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, EGFR Mutation-Related Tumors | 10/25 | 10/25 | | |
| Active, not recruiting | 1 | 46 | Japan | ONO-4578, letrozole, Palbociclib, abemaciclib | Ono Pharmaceutical Co. Ltd | Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer | 07/25 | 07/25 | | |
NCT06547528: A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL |
|
|
| Recruiting | 1 | 108 | Japan | ONO-4685 | Ono Pharmaceutical Co. Ltd | Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 01/29 | 04/29 | | |
NCT05507515: A Phase 1 Study of ONO-2020 in Healthy Participants |
|
|
| Completed | 1 | 132 | US | ONO-2020, Placebo | Ono Pharmaceutical Co. Ltd | Healthy Volunteers | 12/23 | 12/23 | | |
NCT06532331: A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer |
|
|
| Recruiting | 1 | 87 | Japan | ONO-7475, ONO-4538, Nivolumab, Nab-paclitaxel, Gemcitabine | Ono Pharmaceutical Co. Ltd | Metastatic Pancreatic Cancer | 09/27 | 03/28 | | |
NCT06548217: A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 31 | Japan | ONO-4538HSC | Ono Pharmaceutical Co. Ltd | Advanced or Metastatic Solid Tumors | 02/28 | 02/28 | | |
NCT06541665: Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL |
|
|
| Recruiting | 1 | 20 | Japan | ONO-4059, Tirabrutinib Hydrochloride, Rituximab, Methotrexate, Procarbazine, Vincristine | Ono Pharmaceutical Co. Ltd | Primary Central Nervous System Lymphoma | 04/28 | 08/28 | | |
NCT05332704: Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685 |
|
|
| Completed | 1 | 33 | Europe, RoW | ONO-4685, Placebo | Ono Pharmaceutical Co. Ltd | Plaque Psoriasis | 07/24 | 07/24 | | |
| Recruiting | 1 | 24 | Japan | ONO-7018 | Ono Pharmaceutical Co. Ltd | Non Hodgkin Lymphoma | 07/27 | 12/29 | | |
NCT05079282: Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma |
|
|
| Recruiting | 1 | 217 | US | ONO-4685 | Ono Pharmaceutical Co. Ltd | Relapsed or Refractory T Cell Lymphoma | 06/25 | 06/26 | | |
NCT03155061: Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 183 | Japan | ONO-4578, ONO-4538 | Ono Pharmaceutical Co. Ltd | Advanced or Metastatic Solid Tumors | 01/26 | 01/26 | | |
ONO-7018-01, NCT05515406: A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL |
|
|
| Recruiting | 1 | 108 | US | ONO-7018 | Ono Pharmaceutical Co. Ltd | Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | 12/27 | 12/27 | | |
| Vargas, Karina |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies |
|
|
| Active, not recruiting | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia With Lewy Bodies | 11/24 | 11/24 | | |
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy |
|
|
| Recruiting | 2 | 80 | US | ONO-2808, Placebo | Ono Pharmaceutical Co. Ltd | Multiple System Atrophy (MSA) | 08/25 | 08/25 | | |
